ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Acute Migraine Headache in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00355394
Recruitment Status : Completed
First Posted : July 21, 2006
Results First Posted : August 30, 2013
Last Update Posted : November 30, 2015
Sponsor:
Information provided by (Responsible Party):
Children's Hospital of Philadelphia

Brief Summary:
Migraine is common in children and is one of the most common etiologies of headache leading to emergency room presentation in children. Despite this, few studies have investigated the treatment of acute migraine headache in the emergency room. We will perform a prospective, double-blind, placebo-controlled study of metoclopramide versus placebo in the treatment of acute migraine headache. The primary outcome will be the number of subjects headache free at two hours.

Condition or disease Intervention/treatment Phase
Migrainous Headache Drug: Metoclopramide Other: Placebo Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Acute Migraine Headache in Children
Study Start Date : August 2006
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine

Arm Intervention/treatment
Placebo Comparator: Placebo
Standard care including intravenous fluid, but no metoclopramide.
Other: Placebo
Standard care including intravenous fluid, but no metoclopramide.

Active Comparator: Metoclopramide
Standard care including intravenous fluid PLUS metoclopramide.
Drug: Metoclopramide
Intravenous bolus administration.
Other Name: Reglan




Primary Outcome Measures :
  1. The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. [ Time Frame: 2 hours ]
    The NRS is a 0 to 10 point scale with 0 representing no headache and 10 representing severe headache.


Secondary Outcome Measures :
  1. The Number of Subjects With a NRS Score of Zero at One Hour. [ Time Frame: 1 hour ]
    The NRS is a 0 to 10 point scale with 0 representing no headache and 10 representing severe headache.

  2. The Number of Subjects With a NRS Score of Zero at 24 Hours. [ Time Frame: 24 hours ]
    The NRS is a 0 to 10 point scale with 0 representing no headache and 10 representing severe headache.

  3. Change in Headache Intensity as Measured by the NRS Score From Baseline to the One Hour Assessment. [ Time Frame: 1 hours ]
    The NRS is a 0 to 10 point scale with 0 representing no headache and 10 representing severe headache.

  4. Change in Headache Intensity as Measured by the NRS Score From Baseline to the Two Hour Assessment. [ Time Frame: 2 hours ]
    The NRS is a 0 to 10 point scale with 0 representing no headache and 10 representing severe headache.

  5. Change in Headache Intensity as Measured by the NRS Score From Baseline to the 24 Hour Assessment. [ Time Frame: 24 hours ]
    The NRS is a 0 to 10 point scale with 0 representing no headache and 10 representing severe headache.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or Females age 8-18 years
  2. Girls 11 years or older must have a negative urine/serum pregnancy test.
  3. Diagnosis of pediatric migrainous headache. The criteria for pediatric migraine headache based on the most recent ICHD criteria are listed below. The requirement of 5 attacks (A) will not be required for this study, this making the diagnosis migrainous headache. As described elsewhere in the protocol, this change is required to make the study applicable to ED patients who require treatment before five attacks have occurred.

Exclusion Criteria:

  1. Evidence that headache is due to a secondary underlying disorder based on history or physical examination.
  2. Pregnant or lactating females.
  3. Any investigational drug use within 30 days.
  4. Known to have a contraindication to metoclopramide or valproic acid such as pregnancy, liver disease, hematologic disease, or metabolic disease.
  5. Have used metoclopramide (or other antidopaminergic medications) or valproic acid within two days of presentation.
  6. Severe developmental disorders or mental retardation if insufficient information can be obtained to make a clear diagnosis of migraine or judge headache severity.
  7. If patients re-present to the ED, they can not be re-enrolled.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00355394


Locations
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Children's Hospital of Philadelphia
Investigators
Principal Investigator: Nicholas S Abend, MD Children's Hospital of Philadelphia

Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT00355394     History of Changes
Other Study ID Numbers: 2006-4-4755
First Posted: July 21, 2006    Key Record Dates
Results First Posted: August 30, 2013
Last Update Posted: November 30, 2015
Last Verified: October 2015

Additional relevant MeSH terms:
Headache
Migraine Disorders
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Metoclopramide
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action